Meldonium vs Telmisartan
Moderate Research vs FDA Approved
synergistic Researched · 95% Telmisartan (an angiotensin II receptor blocker with PPAR-gamma agonist activity) and meldonium offer complementary mechanisms for cardiac protection. Telmisartan provides afterload reduction, anti-inflammatory effects, and metabolic benefits via PPAR-gamma activation, while meldonium optimizes cardiac energy metabolism and reduces ischemic damage. The combination is particularly relevant for steroid users seeking comprehensive cardiovascular protection, as telmisartan also addresses blood pressure elevation common with androgen use.
Molecular Data
Meldonium Telmisartan
Weight 146.19 Da 514.62 Da
Half-life ~4-6 hours ~24 hours
Type Hydrazinium derivative (C6H14N2O2) Benzimidazole derivative (C33H30N4O2)
Key Benefits
Meldonium
01 Cardioprotective effects through metabolic optimization under ischemic conditions
02 Shifts cardiac energy metabolism from fatty acid oxidation to more oxygen-efficient glucose oxidation
03 Reduces accumulation of toxic fatty acid intermediates (long-chain acylcarnitines) in heart tissue
04 Promotes nitric oxide synthesis and endothelial function via GBB accumulation
05 May improve exercise capacity and reduce recovery time through enhanced glucose utilization
06 Used as adjunctive cardiac protection during anabolic steroid cycles to mitigate androgen-induced cardiotoxicity
07 Well-established safety profile in Eastern European clinical use spanning over 30 years
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Side Effects
Meldonium
Mild gastrointestinal discomfort (nausea, dyspepsia, or stomach upset -- typically transient and dose-dependent)
Occasional heartburn or acid reflux, especially at higher doses or when taken on an empty stomach
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Contraindications
Known hypersensitivity to meldonium or any excipients
Pregnancy or breastfeeding (insufficient safety data)
Individuals under 18 years of age
Severe hepatic or renal impairment (limited pharmacokinetic data in these populations)
Increased intracranial pressure (listed as a contraindication in some regional prescribing information)
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Research Evidence
Meldonium Telmisartan
Status Moderate Research FDA Approved
References 4 studies 5 studies
Latest 2016 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.